DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/bnlj5c/venous_leg_ulcers) has announced the addition of the "Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2014" report to their offering.
This report provides comprehensive information on the therapeutic development for Venous Leg Ulcers (Crural ulcer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Leg Ulcers (Crural ulcer) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Smith & Nephew Plc
- CardioVascular BioTherapeutics, Inc.
- Stratatech Corporation
- RegeneRx Biopharmaceuticals, Inc.
- CytoTools AG
- FirstString Research, Inc.
- CoDa Therapeutics, Inc.
- Intralytix, Inc.
- Pergamum AB
- DermaPro CL-05
- Stem Cell Therapy for Venous Leg Ulcers
- Biochaperone PDGF-BB
For more information visit http://www.researchandmarkets.com/research/bnlj5c/venous_leg_ulcers